Trial Profile
A Switch to Once Daily Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed HIV-infected Rwandans is Non-inferior to Continued Nevirapine-based Antiretroviral Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Feb 2016
Price :
$35
*
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary) ; Nevirapine (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- 29 Feb 2016 New trial record